The Senate is poised to vote today on a motion to proceed (MTP) to debate on repealing and possibly replacing the Affordable Care Act (ACA).
Congressional action on repeal and replace took a number of significant turns in the past few days, and next steps still remain uncertain.
In making the case for repealing and replacing the Affordable Care Act (ACA), the president and congressional leadership have cited “rising premiums,” “unaffordable deductibles” and “skyrocketing” out-of-pocket (OOP) costs associated with ACA plans.
On June 22, Senate leadership released their proposed substitute for the House-passed American Health Care Act (AHCA), the Better Care Reconciliation Act of 2017 (BCRA), as a discussion draft.
On June 12, Iowa submitted a sweeping Section 1332 waiver that would replace the Affordable Care Act’s (ACA) premium tax credits with a new state-administered tax credit and a reinsurance program.
On Thursday, May 4, the House passed by a narrow margin the American Health Care Act (AHCA), the House Republican plan to repeal and replace major provisions of the Affordable Care Act (ACA).
Many older Americans have insufficient income and assets to protect them through retirement.
Antitrust enforcement and litigation had a big year in 2016. In this article, we look back at the most significant cases for the healthcare industry over the last year to identify key trends to watch for in 2017.
Gene therapy is the therapeutic delivery of polymers into a patient’s cells for the purpose of treating a disease. Polymers interfere with gene expression or correct mutations.
As the incoming Congress and administration develop plans to “repeal and replace” the Affordable Care Act (ACA), analysis of five earlier repeal and replace proposals provides insights into the key features likely to appear in any forthcoming repeal and replace legislation.